JAK1 pathway inhibitors for the treatment of vitiligo
US11957661B2 · kind B2 · utility
2Cited by
39References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 8, 2021 |
| Grant date | Apr 16, 2024 |
| Priority date | — |
| Expiry date | Dec 8, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.